Biogen (BIIB) falls as earnings, revenue misses consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Rescue work underway after quakes rock Venezuela, 'high casualties' likely
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
Biogen (BIIB) Misses Q4 EPS by 23c, Offers Guidance
February 13, 2024 7:00 AM ESTBiogen (NASDAQ: BIIB) reported Q4 EPS of $2.95, $0.23 worse than the analyst estimate of $3.18. Revenue for the quarter came in at $2.4 billion versus the consensus estimate of $2.47 billion.
GUIDANCE:
Biogen sees FY2024 EPS of $15.00-$16.00, versus the consensus of $15.64.
For earnings history and earnings-related data on Biogen (BIIB) click here.
... MoreBiogen (BIIB) Granted EU Approval of SKYCLARYS
February 12, 2024 4:06 PM ESTBiogen Inc. (Nasdaq: BIIB) announced the European Commission (EC) has authorized SKYCLARYS® (omaveloxolone) for the treatment of Friedreichs ataxia (FA) in adults and adolescents aged 16 years and older. SKYCLARYS is the first treatment approved within the European Union for this rare, genetic, progressive neurodegenerative disease.1
In my clinical practice, I have seen the devastating impact that Friedreichs ataxia has on patients and... More
AptarGroup (ATR) and Biogen (BIIB) to Operate and Develop Digital Health Solutions
February 9, 2024 10:00 AM ESTAptar Digital Health, part of AptarGroup, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, has entered into an enterprise agreement with Biogen Inc. (Nasdaq: BIIB) to operate and develop digital health solutions for neurological and rare diseases. As part of the agreement, Biogen will transfer ownership of select digital health solutions to Aptar Digital Health (Aptar).
Through this collaboration, Aptar will provide a full range of capabilities including the product management, design, development and maintenance of... More
